All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias Emergency room visit or hospitalizationdetailed results ACTIV-6, 2022 1.10 [0.64; 1.91]
ACTIV-6 (ivermectine), 2023 0.94 [0.58; 1.53]
COVID-OUT (fluvoxamine), 2022 1.17 [0.57; 2.40]
COVID-OUT (ivermectin), 2022 1.39 [0.72; 2.69]
COVID-OUT (metformin), 2022 0.58 [0.35; 0.95]
TOGETHER, 0 1.15 [0.66; 1.99]
TOGETHER interferon lambda, 2022 0.47 [0.29; 0.77]
0.88 [0.65 ; 1.20 ] ACTIV-6, 2022, ACTIV-6 (ivermectine), 2023, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, COVID-OUT (metformin), 2022, TOGETHER, 0, TOGETHER interferon lambda, 2022 7 54% 6,325 low serious death D28detailed results C3PO, 2020 5.02 [0.58; 43.27]
Clemency, 2021 1.03 [0.02; 52.20]
COMET-ICE, 2021 0.25 [0.01; 5.55]
CoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25]
CT-P59 3.2 part 2, 2021 0.50 [0.05; 5.54]
EPIC-HR, 2021 0.04 [0.00; 0.70]
Ezer N (CONTAIN), 2021 0.93 [0.02; 47.48]
Fischer (all doses), 2021 0.22 [0.01; 6.60]
MOVe-OUT, 2021 0.06 [0.00; 1.05]
PINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30]
PRINCIPLE (COLCHICINE), 2021 0.42 [0.01; 12.75]
TOGETHER, 2021 0.69 [0.37; 1.30]
TOGETHER interferon lambda, 2022 0.28 [0.03; 2.49]
University of Minnesota, 2021 1.02 [0.02; 52.15]
0.60 [0.36 ; 0.99 ] C3PO, 2020, Clemency, 2021, COMET-ICE, 2021, CoV-Early (Gharbharan), 2022, CT-P59 3.2 part 2, 2021, EPIC-HR, 2021, Ezer N (CONTAIN), 2021, Fischer (all doses), 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE (COLCHICINE), 2021, TOGETHER, 2021, TOGETHER interferon lambda, 2022, University of Minnesota, 2021 14 0% 11,352 moderate low deathsdetailed results ACTIV-2 (BRII-196 and BRII-198), 0 0.05 [0.00; 0.94]
ACTIV-6 (ivermectine), 2023 2.01 [0.07; 59.98]
BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1.15 [0.02; 58.61]
BLAZE-1 phase 3 (combo), 2021 0.05 [0.00; 0.84]
C3PO, 2020 5.02 [0.58; 43.27]
Clemency, 2021 1.03 [0.02; 52.20]
COLCORONA, 2021 0.56 [0.19; 1.66]
COMET-ICE, 2021 0.25 [0.01; 5.55]
COMIHY, 2020 1.00 [0.02; 57.31]
CONV-ERT, 2021 0.20 [0.01; 4.07]
COPE – Coalition V, 2022 1.56 [0.39; 6.24]
Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.45 [0.05; 3.82]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1.01 [0.02; 51.05]
CoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25]
COVID-PEP Severity (Skipper), 2020 1.01 [0.06; 16.28]
EPIC-HR, 2021 0.04 [0.00; 0.70]
Ezer N (CONTAIN), 2021 0.93 [0.02; 47.48]
Fischer (all doses), 2021 0.22 [0.01; 6.60]
IVERCORCOVID19 (Vallejos), 2020 1.34 [0.30; 6.03]
Lopez-Medina, 2021 0.50 [0.02; 14.95]
MOVe-OUT, 2021 0.06 [0.00; 1.05]
PATCH Cohort 1 (Amaravadi), 2021 0.86 [0.02; 46.71]
PINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30]
PRINCIPLE, 2021 1.65 [0.03; 83.12]
PRINCIPLE (COLCHICINE), 2021 0.42 [0.01; 12.75]
Reis (Hydroxychloroquine) (TOGETHER), 2021 0.26 [0.01; 5.88]
Thomas (vitamin c only), 2021 2.11 [0.07; 64.28]
Thomas (vitamin c plus zinc), 2021 3.54 [0.16; 80.27]
TOGETHER, 2021 0.80 [0.43; 1.50]
TOGETHER (ivermectine), 2022 0.87 [0.48; 1.58]
TOGETHER interferon lambda, 2022 0.28 [0.03; 2.49]
University of Minnesota, 2021 1.02 [0.02; 52.15]
0.73 [0.53 ; 1.01 ] ACTIV-2 (BRII-196 and BRII-198), 0, ACTIV-6 (ivermectine), 2023, BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, BLAZE-1 phase 3 (combo), 2021, C3PO, 2020, Clemency, 2021, COLCORONA, 2021, COMET-ICE, 2021, COMIHY, 2020, CONV-ERT, 2021, COPE – Coalition V, 2022, Cov-2067 Weinreich (1200mg) Cohort 1, 2020, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, CoV-Early (Gharbharan), 2022, COVID-PEP Severity (Skipper), 2020, EPIC-HR, 2021, Ezer N (CONTAIN), 2021, Fischer (all doses), 2021, IVERCORCOVID19 (Vallejos), 2020, Lopez-Medina, 2021, MOVe-OUT, 2021, PATCH Cohort 1 (Amaravadi), 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021, Reis (Hydroxychloroquine) (TOGETHER), 2021, Thomas (vitamin c only), 2021, Thomas (vitamin c plus zinc), 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022, TOGETHER interferon lambda, 2022, University of Minnesota, 2021 32 0% 27,333 low low deaths (time to event analysis only)detailed results TOGETHER, 2021 0.80 [0.43; 1.50]
0.80 [0.43 ; 1.50 ] TOGETHER, 2021 1 0% 1,472 NA not evaluable hospitalization or deathdetailed results ACTIV 6 ivermectin, 2022 1.05 [0.43; 2.61]
ACTIV-2 (BRII-196 and BRII-198), 0 0.22 [0.05; 0.91]
ALBERTA HOPE-Covid19, 2021 2.73 [0.14; 52.87]
BLAZE-1 phase 2 (combination with etesevimab), 2020 0.15 [0.02; 1.18]
BLAZE-1 phase 2 (monotherapy), 2020 0.16 [0.02; 1.31]
BLAZE-1 phase 3 (combo), 2021 0.29 [0.15; 0.58]
C3PO, 2020 0.91 [0.63; 1.33]
Clemency, 2021 0.39 [0.09; 1.67]
COLCORONA, 2021 0.79 [0.61; 1.03]
COMET-ICE, 2021 0.21 [0.09; 0.49]
Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.29 [0.12; 0.68]
COVID-OUT (fluvoxamine), 2022 1.11 [0.33; 3.75]
COVID-OUT (ivermectin), 2022 0.73 [0.19; 2.79]
COVID-OUT (metformin), 2022 0.47 [0.20; 1.11]
CT-P59 3.2 part 1, 2021 0.48 [0.19; 1.25]
CT-P59 3.2 part 2, 2021 0.29 [0.16; 0.51]
EPIC-HR, 2021 0.12 [0.06; 0.24]
Hinks (ATOMIC2), 2021 0.91 [0.43; 1.92]
IVERCORCOVID19 (Vallejos), 2020 0.66 [0.33; 1.30]
MOVe-OUT, 2021 0.48 [0.30; 0.78]
PINETREE (GS-US-540-9012), 2021 0.13 [0.03; 0.58]
PRINCIPLE, 2021 0.81 [0.58; 1.13]
PRINCIPLE (COLCHICINE), 2021 1.29 [0.36; 4.67]
STOP COVID 2, 2021 0.92 [0.40; 2.13]
TACKLE, 0 0.47 [0.26; 0.84]
TOGETHER, 2021 0.76 [0.57; 1.02]
0.51 [0.41 ; 0.65 ] ACTIV 6 ivermectin, 2022, ACTIV-2 (BRII-196 and BRII-198), 0, ALBERTA HOPE-Covid19, 2021, BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, BLAZE-1 phase 3 (combo), 2021, C3PO, 2020, Clemency, 2021, COLCORONA, 2021, COMET-ICE, 2021, Cov-2067 Weinreich (1200mg) Cohort 1, 2020, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, COVID-OUT (metformin), 2022, CT-P59 3.2 part 1, 2021, CT-P59 3.2 part 2, 2021, EPIC-HR, 2021, Hinks (ATOMIC2), 2021, IVERCORCOVID19 (Vallejos), 2020, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021, STOP COVID 2, 2021, TACKLE, 0, TOGETHER, 2021 26 65% 24,638 low critical A EFFACER PCR-negative (end of follow-up)detailed results Hinks (ATOMIC2), 2021 0.91 [0.57; 1.46]
0.91 [0.57 ; 1.46 ] Hinks (ATOMIC2), 2021 1 0% 295 NA not evaluable clinical deteriorationdetailed results COMET-ICE, 2021 0.24 [0.10; 0.56]
COVID-OUT (fluvoxamine), 2022 0.94 [0.65; 1.35]
COVID-OUT (ivermectin), 2022 1.05 [0.76; 1.45]
COVID-OUT (metformin), 2022 0.84 [0.65; 1.08]
Lenze (STOP COVID 1), 2020 0.07 [0.00; 1.26]
Lopez-Medina, 2021 0.56 [0.16; 1.95]
PATCH Cohort 1 (Amaravadi), 2021 0.51 [0.07; 3.68]
STOIC, 2021 0.16 [0.03; 0.74]
TOGETHER, 0 1.15 [0.66; 1.99]
TOGETHER, 2021 0.64 [0.47; 0.87]
TOGETHER (ivermectine), 2022 0.90 [0.70; 1.16]
0.77 [0.61 ; 0.97 ] COMET-ICE, 2021, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, COVID-OUT (metformin), 2022, Lenze (STOP COVID 1), 2020, Lopez-Medina, 2021, PATCH Cohort 1 (Amaravadi), 2021, STOIC, 2021, TOGETHER, 0, TOGETHER, 2021, TOGETHER (ivermectine), 2022 11 57% 7,814 moderate critical clinical improvementdetailed results ACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18]
COVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11]
Lopez-Medina, 2021 1.07 [0.87; 1.32]
PRINCIPLE, 2021 1.21 [1.08; 1.36]
PRINCIPLE, 2021 1.08 [0.95; 1.23]
STOIC, 2021 1.50 [0.69; 3.24]
Thomas (vitamin c only), 2021 3.14 [0.60; 16.38]
Thomas (vitamin c plus zinc), 2021 0.85 [0.27; 2.65]
1.12 [1.05 ; 1.19 ] ACTIV 6 ivermectin, 2022, COVID-PEP Severity (Skipper), 2020, Lopez-Medina, 2021, PRINCIPLE, 2021, PRINCIPLE, 2021, STOIC, 2021, Thomas (vitamin c only), 2021, Thomas (vitamin c plus zinc), 2021 8 0% 5,833 moderate not evaluable clinical improvement (14-day)detailed results ACTION, 2021 1.01 [0.75; 1.37]
Clemency, 2021 1.19 [0.78; 1.81]
COVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11]
STOIC, 2021 1.50 [0.69; 3.24]
1.15 [0.94 ; 1.42 ] ACTION, 2021, Clemency, 2021, COVID-PEP Severity (Skipper), 2020, STOIC, 2021 4 0% 1,197 moderate not evaluable clinical improvement (21-day)detailed results Lopez-Medina, 2021 1.28 [0.79; 2.10]
1.28 [0.79 ; 2.10 ] Lopez-Medina, 2021 1 0% 400 NA not evaluable clinical improvement (28-day)detailed results ACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18]
Chahla, 2021 8.71 [1.99; 38.12]
Clemency, 2021 1.28 [0.84; 1.96]
1.43 [0.84 ; 2.44 ] ACTIV 6 ivermectin, 2022, Chahla, 2021, Clemency, 2021 3 76% 2,245 low not evaluable clinical improvement (7-day)detailed results Clemency, 2021 0.92 [0.51; 1.66]
Thomas (vitamin c only), 2021 3.14 [0.60; 16.38]
1.32 [0.44 ; 3.94 ] Clemency, 2021, Thomas (vitamin c only), 2021 2 47% 498 low not evaluable clinical improvement (time to event analysis only)detailed results ACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18]
CT-P59 3.2 part 2, 2021 1.50 [1.30; 1.74]
Lopez-Medina, 2021 1.07 [0.87; 1.32]
PRINCIPLE, 2021 1.08 [0.95; 1.23]
1.17 [0.99 ; 1.37 ] ACTIV 6 ivermectin, 2022, CT-P59 3.2 part 2, 2021, Lopez-Medina, 2021, PRINCIPLE, 2021 4 81% 4,629 low not evaluable hospitalizationdetailed results ACTIV-6, 2022 0.45 [0.04; 5.03]
ACTIV-6 (ivermectine), 2023 2.01 [0.37; 11.03]
BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.75 [0.32; 1.76]
Buonfrate (COVER-HIGH DOSE ARM C), 2022 6.33 [0.30; 132.38]
C3PO, 2020 0.88 [0.57; 1.34]
COLCORONA, 2021 0.79 [0.60; 1.04]
COMET-ICE, 2021 0.20 [0.08; 0.48]
CONV-ERT, 2021 1.05 [0.78; 1.41]
COPE – Coalition V, 2022 0.77 [0.52; 1.13]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.08 [0.00; 1.49]
CoV-Early (Gharbharan), 2022 0.61 [0.28; 1.33]
COVID-OUT (fluvoxamine), 2022 1.11 [0.33; 3.75]
COVID-OUT (ivermectin), 2022 0.73 [0.19; 2.79]
Ezer N (CONTAIN), 2021 1.92 [0.47; 7.89]
Hinks (ATOMIC2), 2021 0.95 [0.46; 1.96]
IVERCORCOVID19 (Vallejos), 2020 0.65 [0.32; 1.32]
MOVe-OUT, 2021 0.49 [0.30; 0.79]
PATCH Cohort 1 (Amaravadi), 2021 1.79 [0.06; 57.93]
PINETREE (GS-US-540-9012), 2021 0.28 [0.10; 0.77]
PRINCIPLE, 2021 0.94 [0.50; 1.75]
PRINCIPLE (COLCHICINE), 2021 1.73 [0.43; 7.07]
Reis (Hydroxychloroquine) (TOGETHER), 2021 0.76 [0.30; 1.90]
Rodrigues, 2021 2.02 [0.07; 62.02]
Roozbeh, 2020 0.23 [0.02; 2.21]
STOP COVID 2, 2021 0.92 [0.40; 2.13]
Thomas (vitamin c only), 2021 0.68 [0.11; 4.27]
Thomas (vitamin c plus zinc), 2021 2.15 [0.53; 8.80]
TOGETHER, 2021 0.76 [0.57; 1.02]
TOGETHER (ivermectine), 2022 0.81 [0.59; 1.11]
TOGETHER interferon lambda, 2022 0.56 [0.33; 0.96]
University of Minnesota, 2021 3.16 [0.32; 31.34]
0.77 [0.67 ; 0.89 ] ACTIV-6, 2022, ACTIV-6 (ivermectine), 2023, BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, Buonfrate (COVER-HIGH DOSE ARM C), 2022, C3PO, 2020, COLCORONA, 2021, COMET-ICE, 2021, CONV-ERT, 2021, COPE – Coalition V, 2022, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, CoV-Early (Gharbharan), 2022, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, Ezer N (CONTAIN), 2021, Hinks (ATOMIC2), 2021, IVERCORCOVID19 (Vallejos), 2020, MOVe-OUT, 2021, PATCH Cohort 1 (Amaravadi), 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021, Reis (Hydroxychloroquine) (TOGETHER), 2021, Rodrigues, 2021, Roozbeh, 2020, STOP COVID 2, 2021, Thomas (vitamin c only), 2021, Thomas (vitamin c plus zinc), 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022, TOGETHER interferon lambda, 2022, University of Minnesota, 2021 31 20% 22,900 low low mechanical ventilationdetailed results C3PO, 2020 1.49 [0.25; 9.02]
COLCORONA, 2021 0.53 [0.25; 1.11]
COPE – Coalition V, 2022 1.32 [0.46; 3.79]
IVERCORCOVID19 (Vallejos), 2020 1.34 [0.30; 6.03]
PRINCIPLE, 2021 0.50 [0.10; 2.60]
PRINCIPLE, 2021 1.02 [0.45; 2.33]
0.85 [0.55 ; 1.30 ] C3PO, 2020, COLCORONA, 2021, COPE – Coalition V, 2022, IVERCORCOVID19 (Vallejos), 2020, PRINCIPLE, 2021, PRINCIPLE, 2021 6 0% 9,480 moderate not evaluable Recovery (time to event analysis only)detailed results ACTIV-6 (ivermectine), 2023 1.02 [0.92; 1.13]
Buonfrate (COVER-HIGH DOSE ARM C), 2022 0.79 [0.42; 1.48]
CT-P59 3.2 part 2, 2021 1.50 [1.30; 1.74]
1.14 [0.81 ; 1.60 ] ACTIV-6 (ivermectine), 2023, Buonfrate (COVER-HIGH DOSE ARM C), 2022, CT-P59 3.2 part 2, 2021 3 90% 2,585 low not evaluable symptomatic Covid-19detailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.56 [0.31; 1.00]
0.56 [0.31 ; 1.00 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1 0% 204 NA not evaluable viral clearance detailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 1.65 [0.91; 3.00]
BLAZE-1 phase 2 (monotherapy), 2020 0.67 [0.33; 1.38]
Chaccour, 2020 0.92 [0.77; 1.09]
Fischer (all doses), 2021 14.50 [1.70; 123.69]
Podder, 2020 0.47 [0.04; 5.69]
Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.86 [0.46; 1.61]
Q-PROTECT -HCQ alone, 2020 0.88 [0.53; 1.45]
Reis (Hydroxychloroquine) (TOGETHER), 2021 0.92 [0.82; 1.03]
Rodrigues, 2021 1.00 [0.42; 2.39]
TOGETHER, 2021 0.67 [0.42; 1.06]
0.92 [0.79 ; 1.07 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, Chaccour, 2020, Fischer (all doses), 2021, Podder, 2020, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Q-PROTECT -HCQ alone, 2020, Reis (Hydroxychloroquine) (TOGETHER), 2021, Rodrigues, 2021, TOGETHER, 2021 10 31% 2,185 moderate low viral clearance by day 14detailed results IVERCORCOVID19 (Vallejos), 2020 0.76 [0.45; 1.28]
Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.55 [0.32; 0.94]
Q-PROTECT -HCQ alone, 2020 0.88 [0.53; 1.45]
Reis (Hydroxychloroquine) (TOGETHER), 2021 0.92 [0.82; 1.03]
0.85 [0.70 ; 1.02 ] IVERCORCOVID19 (Vallejos), 2020, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Q-PROTECT -HCQ alone, 2020, Reis (Hydroxychloroquine) (TOGETHER), 2021 4 22% 1,462 moderate not evaluable viral clearance by day 7detailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 1.31 [0.61; 2.83]
BLAZE-1 phase 2 (monotherapy), 2020 0.91 [0.39; 2.09]
BLAZE-4, 0 0.37 [0.20; 0.66]
Chaccour, 2020 0.92 [0.77; 1.09]
Feld, 2021 4.12 [1.08; 15.71]
Fischer (all doses), 2021 14.50 [1.70; 123.69]
Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.86 [0.46; 1.61]
Q-PROTECT -HCQ alone, 2020 1.05 [0.53; 2.09]
Rodrigues, 2021 1.00 [0.42; 2.39]
TOGETHER, 2021 0.67 [0.42; 1.06]
TOGETHER (ivermectine), 2022 0.99 [0.59; 1.67]
0.93 [0.70 ; 1.23 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, BLAZE-4, 0, Chaccour, 2020, Feld, 2021, Fischer (all doses), 2021, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Q-PROTECT -HCQ alone, 2020, Rodrigues, 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022 11 57% 2,440 low low emergency room observation for > 6 hours or hospitalizationdetailed results TOGETHER, 2021 0.64 [0.47; 0.87]
0.64 [0.47 ; 0.87 ] TOGETHER, 2021 1 0% 1,497 NA not evaluable ICU admissiondetailed results COPE – Coalition V, 2022 0.84 [0.43; 1.63]
PRINCIPLE, 2021 0.54 [0.24; 1.21]
PRINCIPLE, 2021 0.76 [0.18; 3.18]
University of Minnesota, 2021 1.02 [0.06; 16.66]
0.72 [0.45 ; 1.15 ] COPE – Coalition V, 2022, PRINCIPLE, 2021, PRINCIPLE, 2021, University of Minnesota, 2021 4 0% 4,097 moderate not evaluable recoverydetailed results ACTIV-6, 2022 0.96 [0.86; 1.07]
Ezer N (CONTAIN), 2021 1.25 [0.71; 2.22]
PRINCIPLE, 2021 1.21 [1.08; 1.36]
PRINCIPLE (COLCHICINE), 2021 0.92 [0.72; 1.17]
1.05 [0.89 ; 1.24 ] ACTIV-6, 2022, Ezer N (CONTAIN), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021 4 69% 4,275 moderate not evaluable AE leading to drug discontinuationdetailed results Fischer (all doses), 2021 0.88 [0.08; 9.94]
MOVe-OUT, 2021 0.49 [0.23; 1.05]
PINETREE (GS-US-540-9012), 2021 0.40 [0.08; 2.09]
TOGETHER, 2021 1.38 [0.98; 1.95]
0.79 [0.37 ; 1.69 ] Fischer (all doses), 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, TOGETHER, 2021 4 60% 3,672 moderate not evaluable emergent treatment-resistant variantsdetailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 0.18 [0.02; 1.51]
BLAZE-1 phase 2 (monotherapy), 2020 1.52 [0.51; 4.47]
0.64 [0.08 ; 4.94 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020 2 67% 497 moderate not evaluable related AE (TRAE)detailed results COLCORONA, 2021 1.74 [1.50; 2.03]
EPIC-HR, 2021 1.76 [1.10; 2.82]
1.74 [1.51 ; 2.01 ] COLCORONA, 2021, EPIC-HR, 2021 2 0% 5,761 low not evaluable related SAE (TRSAE)detailed results EPIC-HR, 2021 1.01 [0.25; 4.05]
1.01 [0.25 ; 4.05 ] EPIC-HR, 2021 1 0% 1,349 NA not evaluable serious adverse eventsdetailed results COLCORONA, 2021 0.77 [0.60; 1.00]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.25 [0.03; 2.23]
Fischer (all doses), 2021 1.34 [0.14; 13.10]
Lenze (STOP COVID 1), 2020 0.17 [0.02; 1.49]
Lopez-Medina, 2021 1.00 [0.14; 7.17]
MOVe-OUT, 2021 0.70 [0.48; 1.03]
PINETREE (GS-US-540-9012), 2021 0.25 [0.09; 0.69]
0.66 [0.49 ; 0.89 ] COLCORONA, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, Fischer (all doses), 2021, Lenze (STOP COVID 1), 2020, Lopez-Medina, 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021 7 20% 7,450 low not evaluable adverse eventsdetailed results BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 178.20 [73.71; 430.85]
Chaccour, 2020 1.00 [0.20; 5.07]
COMET-ICE, 2021 0.91 [0.68; 1.22]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.55 [0.34; 0.86]
COVID-PEP Severity (Skipper), 2020 2.75 [1.80; 4.21]
Ezer N (CONTAIN), 2021 0.82 [0.43; 1.57]
Fischer (all doses), 2021 1.05 [0.54; 2.02]
Lenze (STOP COVID 1), 2020 0.98 [0.40; 2.38]
MOVe-OUT, 2021 0.89 [0.71; 1.11]
PINETREE (GS-US-540-9012), 2021 0.85 [0.61; 1.19]
1.59 [0.86 ; 2.93 ] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, Chaccour, 2020, COMET-ICE, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, COVID-PEP Severity (Skipper), 2020, Ezer N (CONTAIN), 2021, Fischer (all doses), 2021, Lenze (STOP COVID 1), 2020, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021 10 94% 4,690 moderate low 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-03 19:47 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 97
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290